Program
budoprutug
Also written as “Budoprutug” and “VB119”.
Its studies are mostly in Glomerulonephritis, Membranous · Lupus Erythematosus, Systemic · Purpura, Thrombocytopenic, Idiopathic · Nephrosis, Lipoid, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Climb Bio | 54 open or running | phase 2since Jun 20, 2025 | May 6, 2025 | Apr 2027phase 1 · NCT07011043 |
| Tenet Medicines | 30 open or running | phase 2since Nov 23, 2020 | Nov 23, 2020 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Nov 23, 2020First study: phase 2 study in Glomerulonephritis, MembranousNew to Tenet MedicinesTenet Medicines · NCT04652570 · 6 enrolled · United States
- Jun 7, 2022Phase 2 study in Nephrosis, LipoidTenet Medicines · NCT05441826 · 1 enrolled · United States
- Aug 19, 2024Phase 2 study in Lupus Erythematosus, SystemicTenet Medicines · NCT06570434
- May 6, 2025Climb Bio's first study: phase 1 study in Lupus Erythematosus, SystemicNew to Climb BioClimb Bio · NCT07011043 · 30 planned · United States, Bulgaria, Georgia and more
- Jun 20, 2025Phase 2 study in Purpura, Thrombocytopenic, IdiopathicClimb Bio · NCT07043946 · 24 planned · Bulgaria, Greece, Serbia and more
- Jul 21, 2025Early phase 1 study in Healthy VolunteersClimb Bio · NCT07090655 · 30 enrolled · Australia
- Jul 24, 2025Phase 2 study in Primary Membranous NephropathyClimb Bio · NCT07096843 · 45 planned · United States, Argentina, Brazil and more
- Apr 27, 2026Phase 2 study in Systemic Lupus ErthematosusClimb Bio · NCT07564596 · 30 planned · China
Ahead
- Apr 2027Primary completion: phase 1 study in Lupus Erythematosus, SystemicClimb Bio · NCT07011043
- Aug 2027Primary completion: phase 2 study in Purpura, Thrombocytopenic, IdiopathicClimb Bio · NCT07043946
- Sep 2027Primary completion: phase 2 study in Systemic Lupus ErthematosusClimb Bio · NCT07564596
- Oct 2027Primary completion: phase 2 study in Primary Membranous NephropathyClimb Bio · NCT07096843
TargetBeta
“Budoprutug is a humanized, immunoglobulin (Ig) G1 monoclonal antibody that selectively binds to CD19 and is projected to deplete targeted cells through antibody-dependent cellular cytotoxicity.”study text, by rule · the study
Other programs on CD19
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| blinatumomabrule | Amgen | phase 4 | 29 |
| inebilizumabrule | Amgen | phase 4 | 19 |
| Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012F | AstraZeneca | phase 3 | 12 |
| axicabtagene ciloleucelrule | Gilead Sciences | phase 3 | 10 |
| surovatamig | AstraZeneca | phase 3 | 10 |
| lisocabtagene maraleucelrule | Bristol-Myers Squibb | phase 3 | 10 |
| Anti-CD19/CD3 Bispecific Antibody MK-1045 | Merck | phase 3 | 8 |
| obexelimab | zenas-biopharma-usa-llc | phase 3 | 7 |
| Autologous Anti-CD19 CAR-T Cells CABA-201rule | cabaletta-bio | phase 3 | 6 |
| zolacabtagene autoleucel | Bristol-Myers Squibb | phase 3 | 6 |
| Autologous Anti-CD19/Anti-CD20 CAR-T Cells KITE-753rule | Gilead Sciences | phase 3 | 2 |
| rondecabtagene autoleucelrule | lyell-immunopharma-inc | phase 3 | 2 |
Studies
All 8 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07564596Systemic Lupus Erthematosus · China | 2 | Recruiting | Climb Bio | Sep 2027 | 30 |
| NCT07096843Primary Membranous Nephropathy · United States, Argentina, Brazil and more | 2 | Recruiting | Climb Bio | Oct 2027 | 45 |
| NCT07090655Healthy Volunteers · Australia | Early 1 | Completed | Climb Bio | Apr 7, 2026 | 30 |
| NCT07043946Purpura, Thrombocytopenic, Idiopathic · Bulgaria, Greece, Serbia and more | 2 | Recruiting | Climb Bio | Aug 2027 | 24 |
| NCT07011043Lupus Erythematosus, Systemic · United States, Bulgaria, Georgia and more | 1 | Recruiting | Climb Bio | Apr 2027 | 30 |
| NCT06570434Lupus Erythematosus, Systemic | 2 | Withdrawn | Tenet Medicines | Dec 2026 | 0 |
| NCT05441826Nephrosis, Lipoid · United States | 2 | Terminated | Tenet Medicines | May 3, 2023 | 1 |
| NCT04652570Glomerulonephritis, Membranous · United States | 2 | Terminated | Tenet Medicines | Nov 21, 2023 | 6 |
How it is read
Names in the registry
- “Budoprutug”, 4 entries
- “budoprutug”, 2 entries
- “VB119”, 2 entries
Conditions, from the studies’ own filings
- Glomerulonephritis, Membranous, 2 studies
- Lupus Erythematosus, Systemic, 2 studies
- Purpura, Thrombocytopenic, Idiopathic, 1 study
- Nephrosis, Lipoid, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.